Join
Live feed
·
FDARegulatoryvia Quantisnow
Neurocrine Biosciences Inc. logo

December 13, 2024 - FDA Approves New Treatment for Congenital Adrenal Hyperplasia

ByQuantisnow·Wall Street's wire, on your screen.
NBIX· Neurocrine Biosciences Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NBIX (Neurocrine Biosciences Inc.) and more on Quantisnow.